Add-on therapy with different non-steroidal anti-inflammatory agents in the management of non-infectious, non-necrotizing episcleritis
Medical hypothesis, discovery & innovation in optometry,
Vol. 2 No. 4 (2021),
15 August 2022
AbstractBackground: Episcleritis is a common ocular inflammatory disease that can cause red eye. It is usually managed using single or combined topical corticosteroids and topical or oral non-steroidal anti-inflammatory drugs (NSAIDs) as directed by clinical response. However, recurrence is possible. This study aimed to compare the effects of add-on therapies using different topical NSAIDs in the management of treatment-naive, non-infectious, non-necrotizing episcleritis.
Methods: Seventy-five eyes of 75 patients with non-infectious, non-necrotizing unilateral episcleritis were included in this study. Patients were allocated to one of three groups based on the NSAID used as add-on therapy: topical diclofenac sodium 0.1% (group D), topical nepafenac 0.1% (group N1), and topical nepafenac 0.3% (group N3). The time to symptom disappearance was defined as the recovery time.
Results: There were no statistically significant differences in age, sex, initial best-corrected distance visual acuity, and intraocular pressure between groups (all P > 0.05). The mean recovery times of groups D and N1 were comparable (12.86 ± 5.35 days and 11.45 ± 5.42 days, respectively) (P > 0.05). However, the mean recovery time of group N3 was significantly shorter (9.70 ± 3.80 days, P < 0.05). Recurrence was observed in only one patient in group N1 at 3 months, and symptoms resolved when the same medication was reinstituted. Furthermore, we noted no side effects during the follow-up period for any of the treatment modalities.
Conclusions: All three topical NSAIDs were effective add-on therapies in the management of non-infectious, non-necrotizing unilateral episcleritis. However, once-daily administration of topical nepafenac 0.3% had a shorter recovery time than topical diclofenac 0.1% and topical nepafenac 0.1%.
- Anti-inflammatory agents
- ocular surface
- red eye
Schonberg S, Stokkermans TJ. Episcleritis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. pmid: 30521217
Thong LP, Rogers SL, Hart CT, Hall AJ, Lim LL. Epidemiology of episcleritis and scleritis in urban Australia. Clin Exp Ophthalmol. 2020;48(6):757-766. doi: 10.1111/ceo.13761 pmid: 32279425
Héron E, Bourcier T. Sclérites et épisclérites [Scleritis and episcleritis]. J Fr Ophtalmol. 2017;40(8):681-695. French. doi: 10.1016/j.jfo.2017.04.007 pmid: 28916114
Honik G, Wong IG, Gritz DC. Incidence and prevalence of episcleritis and scleritis in Northern California. Cornea. 2013;32(12):1562-6. doi: 10.1097/ICO.0b013e3182a407c3 pmid: 24145628
Homayounfar G, Nardone N, Borkar DS, Tham VM, Porco TC, Enanoria WT,et al. Incidence of scleritis and episcleritis: results from the Pacific Ocular Inflammation Study. Am J Ophthalmol. 2013;156(4):752-8. doi: 10.1016/j.ajo.2013.05.026 pmid: 23891336
Goyal L, Ajmera K, Pandit R. Reoccurring Episcleritis and the Role of Antioxidants. Cureus. 2022;14(4):e24111. doi: 10.7759/cureus.24111 pmid: 35530867
Ciotoracu AC, Dim?ncescu MG, Mitulescu TC, Haralambie CI, Iorga AM, Busuioc C, et al. A clinical case of recurrent episcleritis as the initial manifestation of granulomatosis with polyangiitis. Rom J Ophthalmol. 2021;65(4):386-390. doi: 10.22336/rjo.2021.76 pmid: 35087982
Senthil S, Choudhari NS, Vaddavalli PK, Murthy S, Reddy JC, Garudadri CS. Etiology and Management of Raised Intraocular Pressure following Posterior Chamber Phakic Intraocular Lens Implantation in Myopic Eyes. PLoS One. 2016 Nov 17;11(11):e0165469. doi: 10.1371/journal.pone.0165469. Erratum in: PLoS One. 2017;12 (2):e0172929. Reddy, Jagadesh [corrected to Reddy, Jagadesh C] pmid: 27855172
Pleyer U, Ursell PG, Rama P. Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they all the same? Ophthalmol Ther. 2013;2(2):55-72. doi: 10.1007/s40123-013-0020-5 pmid: 25135807
Ackerman S, Smith LM, Gomes PJ. Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management. Ther Adv Chronic Dis. 2016;7(1):52-67. doi: 10.1177/2040622315612745 pmid: 26770669
Belkin M. Smoking and the ophthalmologist. Br J Ophthalmol. 2006;90(11):1337-8. doi: 10.1136/bjo.2006.102004 pmid: 17057170
Cunningham ET Jr. Exogenous factors influencing endogenous inflammation: what can patients do to improve control of their own uveitis? Br J Ophthalmol. 2010;94(7):813-4. doi: 10.1136/bjo.2009.178780 pmid: 20606019
Galor A, Feuer W, Kempen JH, Kaçmaz RO, Liesegang TL, Suhler EB, et al. Adverse effects of smoking on patients with ocular inflammation. Br J Ophthalmol. 2010;94(7):848-53. doi: 10.1136/bjo.2009.174466 pmid: 20606023
Boonman ZF, de Keizer RJ, Watson PG. Smoking delays the response to treatment in episcleritis and scleritis. Eye (Lond). 2005;19(9):949-55. doi: 10.1038/sj.eye.6701731 pmid: 15543188
Williams CP, Browning AC, Sleep TJ, Webber SK, McGill JI. A randomised, double-blind trial of topical ketorolac vs artificial tears for the treatment of episcleritis. Eye (Lond). 2005;19(7):739-42. doi: 10.1038/sj.eye.6701632 pmid: 15359265
Aranda JV, Cai CL, Ahmad T, Bronshtein V, Sadeh J, Valencia GB, et al. Pharmacologic synergism of ocular ketorolac and systemic caffeine citrate in rat oxygen-induced retinopathy. Pediatr Res. 2016;80(4):554-65. doi: 10.1038/pr.2016.105 pmid: 27438224
Flach AJ. Topical nonsteroidal antiinflammatory drugs in ophthalmology. Int Ophthalmol Clin. 2002;42(1):1-11. doi: 10.1097/00004397-200201000-00003 pmid: 12189605
Jabs DA, Mudun A, Dunn JP, Marsh MJ. Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol. 2000;130(4):469-76. doi: 10.1016/s0002-9394(00)00710-8 pmid: 11024419
Kolomeyer AM, Ragam A, Shah K, Do BK, Shah VP, Chu DS. Cyclo-oxygenase inhibitors in the treatment of chronic non-infectious, non-necrotizing scleritis and episcleritis. Ocul Immunol Inflamm. 2012;20(4):293-9. doi: 10.3109/09273948.2012.689075 pmid: 22642498
Jones BM, Neville MW. Nepafenac: an ophthalmic nonsteroidal antiinflammatory drug for pain after cataract surgery. Ann Pharmacother. 2013;47(6):892-6. doi: 10.1345/aph.1R757 pmid: 23715071
- Abstract Viewed: 0 times
- Full Text PDF Downloaded: 0 times